Turkish Journal of Medical Sciences
Volume 42
Number 8 Sup. 2

Article 27

1-1-2012

Effects of combined oral contraceptives on the skin of mice
NIBRAS HATIM KHAMEES
INSAF JASIM MAHMOUD
AMAL AL KHATEEB

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KHAMEES, NIBRAS HATIM; MAHMOUD, INSAF JASIM; and KHATEEB, AMAL AL (2012) "Effects of
combined oral contraceptives on the skin of mice," Turkish Journal of Medical Sciences: Vol. 42: No. 8,
Article 27. https://doi.org/10.3906/sag-1202-16
Available at: https://journals.tubitak.gov.tr/medical/vol42/iss8/27

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Original Article

Turk J Med Sci
2012; 42 (Sup.2): 1528-1537
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-1202-16

Effects of combined oral contraceptives on the skin of mice
Nibras Hatim KHAMEES1, Insaf Jasim MAHMOUD2, Amal Al KHATEEB1

Aim: To find the effects of a combination of 2 widely used contraceptives, ethinyl estradiol and cyproterone acetate
(ECPA), on skin and sebaceous gland morphology and dermal vascularity of mice.
Materials and methods: Female mice were divided into groups: treatment with ECPA for 1 month (T) and its control
(C); and cessation of treatment for an additional month (recovery, R) and its control (CR). Body weight, skin histology
and morphometry, and vaginal smears were performed and analyzed.
Results: In the T and R groups, there was a significant increase in epidermal and dermal thickness and dermal vascularity.
In group T, the number and size of sebaceous glands (SGs) decreased. In group R, all features of SGs were similar to
those of group C. Estrous cycle was arrested at the diestrus stage in group T, but regained its regular pattern in group R.
Conclusion: A decrease in the number and size of SGs explains the mechanism through which ECPA acts. The increase
in skin thickness and vascularity explains the enhancement of shape and texture induced by these hormones. The
contraceptive effects of ECPA are confirmed. Changes are reversible after cessation of treatment.
Key words: Combined oral contraceptives, ethinyl estradiol, cyproterone acetate, skin histology

Introduction
Hormonal therapy constitutes one of the treatment
options available to women with acne. The goal of
the therapy is to oppose the effects of androgens on
the sebaceous gland, which in turn reduces sebum
production and potentially leads to an improvement
in acne. Hormonal treatment is an important option
for women who are unresponsive to standard
therapies and it is usually administered as an adjuvant
or an alternative to those with acne of mild to
moderate severity who also require contraception (1).
Furthermore, certain women may be more suited to
hormonal therapy than others, including those with
adult-onset acne, premenstrual flare-up, irregular
menses, or seborrhea (2). These agents suppress
gonadotropin release, which results in the suppression
of ovarian and adrenal androgen precursors, as well

as increasing sex hormone-binding globulin, which
lowers the levels of biologically active testosterone. In
addition, the antiandrogens competitively displace
androgens at the receptor, thereby blocking their
action (3).
Of the products that are available, ethinyl
estradiol/cyproterone acetate (ECPA; Diane 35)
is the most established and has well-documented
efficacy in the treatment of acne. It is considered to
be the gold-standard hormonal therapy for acne. As
well as being effective in milder cases, ECPA is the
only product that is effective in patients with more
severe acne (4). Cyproterone acetate (CPA) is a
progestational antiandrogen that blocks the androgen
receptor. It is available as a monophasic product
(Diane 35), which contains 35 µg ethinyl estradiol
and 2 mg CPA. ECPA is indicated only for women
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who require antiandrogen therapy for acne, alopecia,
or hirsutism. Apart from its antiandrogenic effect,
CPA also has a pronounced progestational action.
Because of its combination with ethinyl estradiol, it
has the properties of a combined oral contraceptive.
It is widely used in many countries (3).

• Recovery group (R): With an average body weight
of 17.6 g at the start of the experiment. They
received the same course as group T, but after the
end of the first month of treatment, they were left
without treatment for another month and then
sacrificed.

Several studies have shown that biochemical and
histometric parameters are suitable to demonstrate
effects of drugs on epidermal metabolism and
histology (5). Little is known of the effects of
hormonal contraceptive agents on skin homeostasis
and sebaceous gland functions. This study examines
the effects of 2 widely used contraceptive agents,
ethinyl estradiol and CPA, on the skin, specifically on
the sebaceous glands.

• Control for recovery group (CR): With an average
body weight of 17.3 g just before the beginning of
the experiment. They received ordinary tap water
as did group C, but were kept for an additional
month to be sacrificed with the group R animals.

Materials and methods

Hormones

Animals
In this experiment, 20 adult female albino mice
(Mus musculus) were used. They were obtained
from the National Center for Fertility Research,
Baghdad, Iraq. The animals were used according to
the general guidelines of laboratory animals (Iraqi
general health law, experimental protocol section,
1981) and according to the protocol of the laboratory
animal center of the University of Baghdad, Iraq. The
experimental protocol was approved by the College
of Medicine, Al Mustansyriyah University, Baghdad,
Iraq, number 6391, on 20 October 2005. The animals’
ages ranged between 2 and 3 months, and their body
weight range was 16–20 g at the beginning of the
experiment.
The animals were divided into 4 groups of 5 mice
each:
• Treated group (T): With an average body weight
of 16.6 g at the start of the experiment. They
received daily doses of CPA and ethinyl estradiol
in the form of oral suspension per os by modified
feeding syringe for 1 month, and were then
sacrificed.
• Control group (C): With an average body weight
of 18.7 g at the start of the experiment. This group
received tap water per os by modified feeding
syringe for 1 month, and were then sacrificed.

All animals were dissected under anesthesia using
chloroform inhalation (5.0% v/v with 2% ethanol).
With the animals under anesthesia and the heart still
beating, a piece of middorsal skin of 1 cm × 1 cm was
removed.
The following hormones were used during the
experiment:
1. CPA: From Schering AG, Germany, in the form of
10-mg oral tablets. The tablets were kept in a cool,
dark, dry place. The dose used in the experiment
was 0.4 mg/kg mouse body weight.
2. Ethinyl estradiol: From Schering AG in the form
of 2-mg oral tablets. The tablets were kept in a
cool, dry place and were protected from light.
The dose used in the experiment was 0.01 mg/kg
mouse body weight.
Tablets of each hormone were ground by mortar
and pestle, and then the powder was weighed
using the Mettler H54 A.R. microbalance (Karl
Kolb, Germany). After that, the powder of each
hormone tablet was mixed with water to form an
oral suspension that was introduced directly into the
stomach or lower esophagus (gavage) of a conscious
mouse (6).
In humans, the effect of ECPA on sebaceous
glands needs at least 6 menstrual cycles to show a
good response (7), which corresponds to 1 month in
mice (5-day cycles).
Animal dosage was calculated according to the
following formula (8):
HED (mg/kg) = animal dose (mg/kg) × animal
km/human Km,
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where HED is the human equivalent dose, and Km
is the conversion factor between body weight in
kilograms and body surface area in square meters
(Km values were obtained from the table in reference
8).
The body weight of animals was recorded at the
beginning of the experiment, weekly thereafter, and
at the end of the experiment using a Mettler E2000
measure (d = 0.1 g). The mean of these weights was
calculated for each group.
A vaginal smear was taken from each animal
daily between 1000 and 1200 hours throughout the
experiment to observe cyclic changes in the estrous
cycle. A final smear was taken at time of dissection.
Each smear was fixed by 95% alcohol and stained
with Papanicolaou stain.
Skin preparation
A middorsal skin patch of about 1 cm × 1 cm
was removed at the time of dissection and coarse
hairs were shaved before the specimen was kept
in formalin, and tissues were processed for light
microscopy according to the method of Bancroft and
Stevens (9). From each animal, 5 different sections
were chosen randomly, and then 4 random readings
were taken from each section, giving a total of 20
random readings per animal.
The skin was examined under a light microscope
for histological changes and 4 statistical parameters
were used to determine the changes in the skin and
sebaceous glands.
1. Epidermal and dermal thickness
For morphometric analysis, epidermal and
dermal thicknesses were measured manually with
a calibrated ocular micrometer scale introduced
into the microscope eyepiece. Linear measurements
of the epidermis were made from the basement
membrane of the stratum basale to the end of the
stratum granulosum in interfollicular sites. The
stratum corneum itself could not be measured,
since it was partially or completely torn off during
sectioning. Dermal measurements were taken from
the basement membrane of the stratum basale, at the
site of epidermal ridges, to the hypodermal fat layer
in interfollicular regions.
1530

2. Morphometric assessments of sebaceous glands
and vascularity
A point-counting method was used to assess
changes in the percentage of sebaceous glands in
the skin samples. A square grid (105 × 105 µm) with
121 intersecting points was used. The number of
intersection points falling on an element of interest
(sebaceous glands or blood vessels) was recorded
and divided by the total number of points to yield the
relative percentage or area fraction of that element
(10).
3. Sebocyte number
Sebocyte and necrotic cell numbers per square
millimeter were calculated by counting their nuclei
using a Zeiss integrating micrometer disk turret
(Germany) and an objective micrometer slide and
lens (Japan) according to the following formula (11):

3
Ai = Pi 2 Z 2
where Ai is the part of the total section area belonging
to the tissue component i (sebaceous gland), Pi is the
number of points falling on the nuclei of that part,
and Z is the equivalent in millimeters of the distance
between 2 points on the integration system.
The mean cell nucleus diameter was then
calculated to determine the numerical density (i.e.
cell number per cubic millimeter of target tissue)
using the following formula (12):
Nv = Na/(D + t),
where Nv is the number of cells per cubic millimeter,
Na is the number of their profile per square millimeter,
D is the mean diameter of the cell nucleus, and t is the
section thickness in millimeter.
4. Sebocyte size
Cellular circular profiles were measured using
an optical micrometer and volume diameter was
calculated using Giger and Riedwyl’s formula (13):
D = (4/π)d,
where D is the mean diameter of the cell and d is the
mean diameter of its circular profiles.
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Vaginal smears
determination

and

estrous

cycle

length

measurement was calculated, and then each group
was compared with its control.

Stages of the estrous cycle were determined by
cytological evaluation of vaginal smears. Warm saline
was gently flushed into the vagina using a soft plastic
pipette between 1000 and 1200 hours daily over a
period spanning at least 6 consecutive cycles. The
lavages were smeared onto glass slides, stained with
Papanicolaou stain, and examined microscopically
to evaluate the cytological features described in
Results below. The average length of each phase
was calculated for each individual mouse and used
to calculate the average length ± standard deviation
(SD) for the entire study group.

Results
Body weight
There was no significant change (P > 0.05) in body
weight acquirement between the treated animals
and their controls over the period of 4 and 8 weeks
(Table 1). The increase in body weight fell within the
expected normal limits for the treated and recovery
animals as concluded from their corresponding
controls.

Analysis of data

Skin histology

By using analysis of variance, the results were
evaluated statistically, and whenever there was a
difference between correlated groups, Student’s t-test
was applied to estimate the degree of significance
by comparing the mean of the data using the SD for
each group (14). The mean ± SD of each numeric

In treated and recovery animals there were more
cell layers in the epidermis as compared to their
corresponding controls (Figures 1a–1c and 2a–2b).
The epidermis was clearly recognized with some
stratum corneal sloughing and prominent cuboidal
basal cells at the stratum basale.

Table 1. Changes in body weight of female albino mice.
Group

Time / body weight (g)
Beginning of experiment

4 weeks

8 weeks

Treated

16.6 ± 1.7

18.6 ± 1.6

-

Control

18.7 ± 1.2

20.7 ± 0.98

-

Recovery

17.6 ± 1.3

18.9 ± 1.1

21.3 ± 0.9

Control of recovery

17.3 ± 2.1

18.7 ± 1.7

19.8 ± 1.3

Data represent mean ± SD. No statistical significance, P > 0.05.

a

b

c

Figure 1. Skin of studied mice: a) skin of control female mouse showing thin epidermis (black bar), low dermal collagen density, lightstaining sebocytic nuclei (narrow arrows), and few pyknotic nuclei (arrow head), H&E, 200×; b) skin of treated female mouse
showing epidermal thickening (black bar), increased collagen density, darker-staining sebocytic nuclei (narrow arrows), and
numerous pyknotic nuclei (arrow heads), H&E, 200×; c) skin of treated female mouse showing increased dermal collagen
content and vascularity (arrow heads), small immature (dark-staining) sebocytes (thick arrows), and several pyknotic nuclei
of sebocytes (narrow arrows) (HF = hair follicle), H&E, 200×.
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b

a

Figure 2. Skin of recovery group animals: a) skin of recovery female mouse showing dermal collagen weaving pattern, increased
vascularity (narrow arrows), and small-sized sebocytes at different stages of growth with peripheral cells (tailed arrow),
maturing cells (double arrow), and holocrine cells with pyknotic nuclei (arrow heads) (HF = hair follicle), H&E, 200×; b)
skin of recovery animal showing increased epidermal thickness (vertical bar) and dermal dense collagenous connective tissue
bundles (arrow heads), H&E, 200×.

In the dermis, dense collagenous connective
tissue bundles were more pronounced in the treated
and recovery animals. These collagen bundles had a
basket weave pattern arrangement (Figures 1 and 2).
Morphometric measurements revealed a
statistically significant increase in epidermal
thickness in treated animals as compared to control
animals (P < 0.05). Epidermal thickness in recovery
animals was also significantly greater than that of
their control (P < 0.05) (Table 2).
There was a highly significant increase in dermal
thickness (P < 0.001) in both treated and recovery
groups as compared to their corresponding controls
(Table 2).

Skin vascularity
An increased vascularity was observed in the treated
and recovery groups. Dilatation of blood vessels
rather than an increase in their number was clearly
obvious (Figures 1c and 2a).
There was a significant increase in blood vessel area
fraction (P < 0.05) in treated and recovery groups as
compared to their corresponding controls (Table 3).
Sebaceous glands
The sebaceous glands appeared smaller in size in
treated animals as compared to the control (Figures
3a and 3b). The sebocytes of treated animals were less
in number and smaller in size with darker nuclei and

Table 2. Changes in epidermal and dermal thickness in female albino mice.
Epidermal thickness
(µm)

Dermal thickness
(µm)

Treated

22.4 ± 0.6*

315.6 ± 33.6**

Control

12.4 ± 0.4

142.6 ± 17.8

Recovery

26.6 ± 1.1*

369.6 ± 18.4**

Control of recovery

14.2 ± 2.3

217 ± 23.3

Group

Data represent mean ± SD. * = statistical significance, P < 0.05; ** = high statistical significance,
P < 0.001.
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Table 3. Changes in skin vascularity.
Group

Dermal blood vessel area fraction (%)

Treated

6.3 ± 1.6*

Control

2.6 ± 0.9

Recovery

5.6 ± 1.1*

Control of recovery

2.1 ± 1.3

Data represent mean ± SD. * = statistical significance, P < 0.05.

a

b

Figure 3. Sebaceous glands of studied mice: a) sebaceous gland of control female mouse showing large sebocytes and lightly staining
nuclei with obviously larger glandular size (arrow head), H&E, 200×; b) sebaceous gland of treated female mouse showing
smaller sebocytes and darkly staining sebocytic nuclei with obviously smaller glandular size (arrow heads), H&E, 200×.

less foamy cytoplasm, and more necrotic cells with
absent or pyknotic nuclei, as compared to the control
animals (Figures 3a and 3b). In recovery animals, all
features of sebaceous glands and their sebocytes were
like those of the control animals (Figure 2a).
The sebaceous glands’ area fraction was
significantly reduced (P < 0.05) in treated animals,
but not in the recovery group (Table 4). The number
and size of sebocytes decreased significantly (P <
0.05) among the treated group, while the increase
in the number of necrotic cells in treated animals
was highly significant (P < 0.001) compared to the
control animals (Table 4).
Vaginal smears and estrous cycle changes
Histological examination of the smears obtained
from control groups showed regular estrous cycles
with a length of 4–5 days, whereas smears obtained
from treated animals showed that the cycle was

arrested at the diestrus stage, starting 4–5 days from
the beginning of the treatment, and remained in this
stage for the whole period of treatment (Figures 4a
and 4b). These treated animals’ smears contained
mainly leucocytes but also a variable number of
epithelial and small cornified cells. The recovery
group regained their regular estrous cycling pattern
during the second 4 weeks of the experiment, after
cessation of treatment (Figure 4c).
Table 5 shows the length of the estrous cycle
and its stages in each animal group. The length of
the whole cycle and the number of cycles during
the treatment period was significantly reduced
(P < 0.05) in both treated and recovery groups
(Table 5). However, the recovery group showed a
more uniform distribution of phases over the cycle
duration. In the treated group, about 78% of the
cycle days were spent in diestrus, compared to 57%
in the recovery group.
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Table 4. Changes in sebaceous gland area fraction (%), sebocyte and necrotic cell number (per mm3), and sebocyte diameter (µm) in
female albino mice.
Sebaceous gland area fraction
(%)

Sebocyte number
(per mm3)

Sebocyte diameter
(µm)

Necrotic cell number
(per mm3)

Treated

17.3 ± 2.1*

220 ± 25.5*

44.1 ± 2.4 *

42.4 ± 7.4**

Control

32 ± 4.2

346 ± 14.2

83.2 ± 1.3

17.5 ± 3

Recovery

29 ± 3.7

310 ± 15.3

78.6 ± 4.1

21.4 ± 1.6

Control of recovery

33 ± 5.6

337 ± 24.2

85.3 ± 2.6

19.5 ± 2.8

Group

Data represent mean ± SD. * = statistical significance, P < 0.05; ** = high statistical significance, P < 0.001.

c

b

a

Figure 4. Vaginal smears of studied mice: a) smear of control mouse showing features of vaginal estrus with fully mature (anucleated)
dark-staining cornified epithelial cells arranged in mucus clusters (arrow heads), H&E, 100×; b) smear of treated mouse
showing persistent diestrus features with abundant inflammatory leukocytes (small rounded cells) with few immature
(nucleated) epithelial cells (arrows), H&E, 100×; c) smear from albino mouse recovery group showing features of metestrus
with dark-staining cornified and nucleated epithelial cells together with numerous inflammatory leukocytes, H&E, 100×.

Table 5. Changes in estrous cycle in female albino mice.

Group

Time (weeks)

Number of cycles
per duration

Treated

4

Control

Duration (days)
Proestrus

Estrus

Metestrus

Diestrus

1.3 ± 0.35 **

1.1 ± 0.1

2.3 ± 0.4

2.6 ± 0.2

22.2 ± 0.6**

4

6.5 ± 0.22

4.9 ± 0.2

7.2 ± 0.2

6.3 ± 0.1

9.7 ± 0.6

Recovery

8

7.1 ± 0.36 **

6.3 ± 0.2

9.9 ± 0.1

9.2 ± 0.3

32.1 ± 0.4**

Control of recovery

8

12.8 ± 0.12

11.6 ± 0.3

16.4 ± 0.5

12.8 ± 0.3

18.8 ± 0.4

Data represent mean ± SD. ** = high statistical significance, P < 0.001.
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Discussion
The absence of a significant difference between the
weights of treated and control animals in this study
may be related to a net effect of weight loss, caused
by estradiol, compensated by weight gain in the
form of fluid retention caused by CPA. Estradiol
causes weight loss by increasing the basal metabolic
rate (15), whereas CPA causes weight gain by water
retention (16).
Estrogen supplementation prevents skin from
aging by increasing its thickness and improving
its moisture (17) and increases collagen protein
levels in aged human skin (18), whereas estrogen
deprivation is associated with skin dryness, atrophy,
fine wrinkling, poor healing, and declining dermal
collagen content with decreased laxity (19). Thus, the
increased dermis thickness of our treated animals is
probably related to increased skin collagen caused by
estrogen.
The epidermal thickening shown in our study
may be explained by increased mitotic activity of
the basal layer induced by estrogen, for estrogen is
proven to stimulate proliferation of keratinocytes
through estrogen alpha receptors (20).
In our study, treatment with estradiol and CPA
was associated with increased dermal vascularity.
Estrogens have been shown to stimulate angiogenesis
through endothelial proliferation and differentiation
by secretion of tissue growth factor beta-1 (21).
However, angiogenesis in adult organisms was
shown to be absent under normal conditions, except
in the ovaries (22). Therefore, it is best to say that
the increased vascularity in our treated animals
was through vasodilatation rather than new vessel
formation (angiogenesis). Such vasodilatation may
have been caused by increased collagen synthesis
and extracellular matrix secretion, requiring a bigger
blood supply and more nutrient delivery.
Combined oral contraceptives have been
successfully used in the treatment of acne, seborrhea,
and alopecia. Estrogens reduce sebum secretion in
both humans and animals by reducing lipogenesis
without affecting the rate of sebocyte cellular
division (23). A possible mechanism for this effect
is the reduction of enzymes required for fatty acid
synthesis and metabolism induced by estrogens (24).

Another mechanism may involve the antagonizing
effect of estrogens to androgenic activity: rats given
testosterone and estrogen simultaneously have a
higher rate of mitosis but a reduction in sebaceous
gland size and sebum secretion (25).
CPA significantly reduces sebaceous cell
proliferation rather than lipogenesis with consequent
reduction in sebum excretion rate, and these effects
are mediated by the antiandrogenic properties of
CPA (26).
In our study, the reduction of sebaceous gland
area fraction and sebocyte size and number suggests
a greater role of estradiol on sebocytic cell lipogenesis
resulting in shrinkage of sebocytes and glandular
surface area, together with the effect of CPA on
the mitotic activity of basal sebocytes and sebocyte
differentiation, which leads to a reduction in sebocyte
number. The absence of a statistically significant
difference in the size and number of the sebocytes
in the recovery group indicates a reversible effect of
estradiol and CPA.
Androgen is essential for sebaceous gland
function and sebocyte proliferation. It is a major
stimulus of sebaceous gland development, sebocyte
differentiation, and sebum secretion (23,27). The
antiandrogenic effect of CPA may have contributed
to the increase in necrotic cells shown in our study.
Antagonization of androgens by CPA led to the failure
of sebocytes to develop into fully mature holocrine
cells, which triggered a cascade of nuclear pyknotic
or cellular apoptotic pathways that led to cell death.
Reduction of the estrous cycles and the persistence
of the vaginal epithelium in the diestrus phase in our
treated animals confirmed the contraceptive actions
of estradiol and CPA. Cyclic changes of the vaginal
epithelium can be seen in vaginal smears, which
gives an indication of ovarian activity (28,29).
In light of the results of the present study, we can
conclude that:
• The combined effects of CPA and ethinyl estradiol
result in counterbalanced changes in body weight.
• The statistical analysis of morphometric and
histological findings indicate that CPA and ethinyl
estradiol significantly reduce sebocyte number
and size, which results in a decrease in sebaceous
1535
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gland size, and this explains the implication of
these hormones in the treatment of acne.
• The increase in thickness of the epidermis and
dermis and the increase in skin vascularity
explain the enhancement of shape and texture of
skin induced by these hormones.

• Our results confirm the contraceptive effects of
the above-mentioned hormones as evidenced by
vaginal smears.
• Most of the histological and morphometric
changes that occur during the period of treatment
are reversible.
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